Humira, manufactured by AbbVie in the United States, did not retain its position as the world’s top-selling medicine in terms of revenue, as it had done in prior years. Covid-19 vaccination Comirnaty was the best-selling pharmaceutical medicine in 2021, bringing in over 37 billion USD. Humira was the second most profitable medicine in 2021, with about 21 billion dollars in sales.
Rheumatoid and psoriatic arthritis are the most common conditions for which Humira is prescribed. However, like many other leading medications, it can be used to treat a far wider spectrum of medical issues. As a result, Crohn’s disease, ankylosing spondylitis, ulcerative colitis, psoriasis, uveitis, and other autoimmune illnesses are all treated with the medicine. Humira is given as an injection under the skin. In the United States, it was approved for the first time in 2002.
Reliance on blockbuster drugs
Blockbuster medications frequently have a significant financial impact on the maker. Pharmaceutical firms might be extremely reliant on their sales performance in some circumstances. Humira accounts for more than 60% of AbbVie’s overall revenue, with the top three medications accounting for more than 80%. Companies that rely on a small number of blockbuster pharmaceuticals may face significant revenue losses. Humira (adalimumab) biosimilars are already on the market and will continue to gain market share in the coming years. Humira, on the other hand, has surpassed the $20 billion revenue mark, defying expectations set years ago.
If you prefer Table data, here it is :
|Product name ( company )||in Billion U.S. dollors|
|Comirnaty (BioNTech ‘Pfizer)||36.9|
|Keytruda (Merck & Co.)||17.2|
|Stelara (Janssen Biotech)||9.1|
|Opdivo (BMSiOno Plum)||7.6|
|Trulicity (Eli Lilly)||6.5|